Clinical Overview
Pregabalin is an anticonvulsant and neuropathic pain agent indicated for diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, and as adjunctive therapy for partial-onset seizures. It represents a significant advancement in neuropathic pain management with proven efficacy across multiple pain conditions.
Primary Clinical Applications
Pregabalin is FDA-approved for diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, and partial-onset seizures in patients 1 month and older. It has also shown efficacy in generalized anxiety disorder in some countries and various off-label neuropathic pain conditions.
Mechanism and Clinical Benefits
Pregabalin binds to the α2-δ subunit of voltage-gated calcium channels, reducing calcium influx and subsequent neurotransmitter release. This mechanism provides effective pain relief and seizure control with generally favorable tolerability compared to older anticonvulsants.
Dosing Flexibility
Available in multiple formulations including immediate-release capsules and extended-release tablets, pregabalin offers flexible dosing options. The medication requires dose adjustment in renal impairment but has minimal drug interactions.
Prescribing Information
Dosing & Administration
Diabetic Peripheral Neuropathy:
- Initial: 50 mg three times daily (150 mg/day)
- Maintenance: May increase to 100 mg three times daily within 1 week
- Maximum: 300 mg/day
Postherpetic Neuralgia:
- Initial: 75 mg twice daily or 50 mg three times daily
- Maintenance: 150-300 mg/day in 2-3 divided doses
- Maximum: 600 mg/day
Fibromyalgia:
- Initial: 75 mg twice daily (150 mg/day)
- Target: 300-450 mg/day in 2 divided doses
- Maximum: 450 mg/day
Partial-Onset Seizures:
- Adults: 150-600 mg/day in 2-3 divided doses
- Pediatric: Weight-based dosing
Indications
- Diabetic peripheral neuropathy
- Postherpetic neuralgia
- Fibromyalgia
- Partial-onset seizures (adjunctive)
Contraindications
- Known hypersensitivity to pregabalin
Warnings & Precautions
- Suicidal thoughts: Monitor for behavioral changes
- Angioedema: Discontinue if occurs
- Hypersensitivity reactions: Rare but serious
- Withdrawal: Taper gradually to avoid seizures
- Renal impairment: Dose adjustment required
Drug Interactions
- CNS depressants: Additive sedation (alcohol, opioids)
- ACE inhibitors: Increased angioedema risk
- Thiazolidinediones: Additive weight gain and edema
Adverse Reactions
Common (≥5%):
- Dizziness, somnolence, peripheral edema, weight gain
Other Notable:
- Blurred vision, dry mouth, constipation, difficulty concentrating
Special Populations
- Renal Impairment: Dose reduction required based on CrCl
- Pregnancy: Category C – use only if benefits outweigh risks
- Elderly: Consider renal function and start with lower doses
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
